0J9P.LSE Incyte Corp.
- Market cap
- -
- P/E
- 29.0x
- P/B
- -
- ROE
- 2.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0J9P.LSE undervalued?
Graham numberThe Graham number of Incyte Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Incyte Corp. fundamental analysis
No fundamental analysis for Incyte Corp. yet.
Incyte Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Incyte Corp.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment…
Full company profileIncyte Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Incyte Corp. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.11B | 1.54B | 1.88B | 2.16B | 2.67B | 2.99B | 3.39B | 3.70B | 4.24B | 5.14B | 6.01B |
| Gross Profit | 1.00B | 1.43B | 1.75B | 2.01B | 2.51B | 2.80B | 3.14B | 1.81B | 3.86B | 4.70B | 5.57B |
| Operating Income | 164M | -236M | 155M | 422M | -240M | 638M | 600M | 652M | 80.1M | 1.34B | 423M |
| EBITDA | 205M | -172M | 210M | 476M | -178M | 630M | 600M | 735M | 408M | 1.44B | 490M |
| Net Income | 104M | -313M | 109M | 447M | -296M | 949M | 341M | 598M | 32.6M | 1.29B | 139M |
| EPS | 0.54 | -1.53 | 0.51 | 2.05 | -1.36 | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 | 0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 1.64B | 2.30B | 2.65B | 3.43B | 3.58B | 4.97B | 5.88B | 6.82B | 5.48B | 6.97B | 7.29B |
| Total Liabilities | 1.22B | 672M | 720M | 828M | 972M | 1.20B | 1.51B | 1.63B | 2.03B | 1.80B | 1.64B |
| Shareholders' Equity | 419M | 1.63B | 1.93B | 2.60B | 2.61B | 3.77B | 4.37B | 5.19B | 3.45B | 5.17B | 5.64B |
| Cash & Short-term Investments | 809M | 1.17B | 1.44B | 2.12B | 1.80B | 2.35B | 3.24B | 3.66B | 2.16B | 3.58B | 3.85B |
| Total Debt | 651M | 24.0M | 17.4M | 72.1M | 61.7M | 60.4M | 55.6M | 52.6M | 60.3M | 69.4M | 37.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 305M | -93.0M | 336M | 711M | -125M | 749M | 970M | 496M | 335M | 1.41B | 269M |
| Capital Expenditure | 120M | 111M | 73.5M | 78.1M | 187M | 181M | 77.8M | 32.5M | 86.3M | 58.9M | 51.0M |
| Free Cash Flow | 184M | -204M | 263M | 633M | -312M | 568M | 892M | 464M | 249M | 1.35B | 218M |
| Ratios | |||||||||||
| ROE | 24.8% | -19.2% | 5.7% | 17.2% | -11.3% | 25.2% | 7.8% | 11.5% | 0.9% | 24.9% | 2.5% |
| ROA | 6.4% | -13.6% | 4.1% | 13.0% | -8.3% | 19.1% | 5.8% | 8.8% | 0.6% | 18.5% | 1.9% |
| Net Profit Margin | 9.4% | -20.4% | 5.8% | 20.7% | -11.1% | 31.8% | 10.0% | 16.2% | 0.8% | 25.0% | 2.3% |
| Debt to Equity | 1.55x | 0.01x | 0.01x | 0.03x | 0.02x | 0.02x | 0.01x | 0.01x | 0.02x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Incyte Corp. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 26.3M | 0.12 | 7.7% |
| 2021 | USD 29.9M | 0.13 | 3.2% |
| 2020 | USD 22.8M | 0.10 | - |
| 2019 | USD 16.8M | 0.08 | 3.7% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Incyte Corp.
- Insiders 1.84%
- Institutions 98.17%
- Public & others 0.00%
- Free float 172M
Incyte Corp. company profile
- Company name
- Incyte Corp.
- Ticker
- 0J9P.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 2,844
- Fiscal year end
- December
- Address
- 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
- Phone
- 302 498 6700
- Website
- incyte.com
About Incyte Corp.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Incyte Corp. management
10- Mr. William J. MeuryCEO & Director · born 1968
- Dr. Pablo J. Cagnoni M.D., Ph.D.President and Global Head of R&D · born 1963
- Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & Chief Accounting Officer · born 1978
- Dr. Steven H. Stein M.D.Executive VP, Head of Late-stage Development & Chief Medical Officer · born 1967
- Mr. Mohamed Khairie IssaExecutive Vice President & Head of U.S. Commercial · born 1983
- Mr. Suketu P. UpadhyayExecutive VP & CFO · born 1969
- Mr. Michael James MorrisseyExecutive VP & Head of Global Technical Operations · born 1964
- Ms. Alexis SmithVP & Head of Investor Relations
- Mr. Richard A. Hoffman J.D., M.B.A.Executive VP, General Counsel & Secretary · born 1962
- Ms. Pamela M. MurphyVP of Investor Relations & Corporate Communications · born 1951